Relmada Therapeutics Shares Gain on Positive Study Results, Financing Agreement

Dow Jones

Mar 09

By Connor Hart

Shares of Relmada Therapeutics jumped after the company said its treatment for non-muscle invasive bladder cancer performed well in a recent trial and would be advanced to late-stage testing.

The stock climbed 51%, to $6.70, in premarket trading Monday.

The biotechnology company said before the bell that its treatment, NDV-01, demonstrated a 12-month complete response rate of 76% during a recent mid-stage study, with a favorable safety profile.

"These 12-month data show the potential durability of NDV-01's clinical response profile," said Raj Pruthi, chief medical officer of oncology.

He added that the interim results provide "meaningful clinical validation of the program" and support the treatment's advancement into a late-stage study.

Relmada separately said Monday it has entered a securities purchase agreement for private investment in public equity financing, expected to result in gross proceeds of about $160 million.

The PIPE financing included participation several firms, including Venrock Healthcare Capital Partners, Commodore Capital and Janus Henderson Investors.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 09, 2026 08:30 ET (12:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2618626398"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618626398\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618626398?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618626398","market":"us","top_or_hot":-1,"title":"Relmada Therapeutics Shares Gain on Positive Study Results, Financing Agreement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> jumped after the company said its treatment for non-muscle invasive bladder cancer performed well in a recent trial and would be advanced to late-stage testing. \n</p>\n<p>\n  The stock climbed 51%, to $6.70, in premarket trading Monday. \n</p>\n<p>\n  The biotechnology company said before the bell that its treatment, NDV-01, demonstrated a 12-month complete response rate of 76% during a recent mid-stage study, with a favorable safety profile. \n</p>\n<p>\n  \"These 12-month data show the potential durability of NDV-01's clinical response profile,\" said Raj Pruthi, chief medical officer of oncology. \n</p>\n<p>\n  He added that the interim results provide \"meaningful clinical validation of the program\" and support the treatment's advancement into a late-stage study. \n</p>\n<p>\n  Relmada separately said Monday it has entered a securities purchase agreement for private investment in public equity financing, expected to result in gross proceeds of about $160 million. \n</p>\n<p>\n  The PIPE financing included participation several firms, including Venrock Healthcare Capital Partners, Commodore Capital and <a href=\"https://laohu8.com/S/JHG\">Janus Henderson</a> Investors. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 08:30 ET (12:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relmada Therapeutics Shares Gain on Positive Study Results, Financing Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelmada Therapeutics Shares Gain on Positive Study Results, Financing Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-09 20:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> jumped after the company said its treatment for non-muscle invasive bladder cancer performed well in a recent trial and would be advanced to late-stage testing. \n</p>\n<p>\n  The stock climbed 51%, to $6.70, in premarket trading Monday. \n</p>\n<p>\n  The biotechnology company said before the bell that its treatment, NDV-01, demonstrated a 12-month complete response rate of 76% during a recent mid-stage study, with a favorable safety profile. \n</p>\n<p>\n  \"These 12-month data show the potential durability of NDV-01's clinical response profile,\" said Raj Pruthi, chief medical officer of oncology. \n</p>\n<p>\n  He added that the interim results provide \"meaningful clinical validation of the program\" and support the treatment's advancement into a late-stage study. \n</p>\n<p>\n  Relmada separately said Monday it has entered a securities purchase agreement for private investment in public equity financing, expected to result in gross proceeds of about $160 million. \n</p>\n<p>\n  The PIPE financing included participation several firms, including Venrock Healthcare Capital Partners, Commodore Capital and <a href=\"https://laohu8.com/S/JHG\">Janus Henderson</a> Investors. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 08:30 ET (12:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618626398","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618626398","pubTimestamp":1773059400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Relmada Therapeutics jumped after the company said its treatment for non-muscle invasive bladder cancer performed well in a recent trial and would be advanced to late-stage testing.The stock climbed 51%, to $6.70, in premarket trading Monday.The biotechnology company said before the bell that its treatment, NDV-01, demonstrated a 12-month complete response rate of 76% during a recent mid-stage study, with a favorable safety profile.\"These 12-month data show the potential durability of NDV-01's clinical response profile,\" said Raj Pruthi, chief medical officer of oncology.He added that the interim results provide \"meaningful clinical validation of the program\" and support the treatment's advancement into a late-stage study.Relmada separately said Monday it has entered a securities purchase agreement for private investment in public equity financing, expected to result in gross proceeds of about $160 million.The PIPE financing included participation several firms, including Ven","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RLMD":"Relmada Therapeutics, Inc.","BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Relmada Therapeutics股价因积极的研究结果和融资协议而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"RLMD":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Relmada Therapeutics jumped after the company said its treatment for non-muscle invasive bladder cancer performed well in a recent trial and would be advanced to late-stage testing. \n\n\n  The stock climbed 51%, to $6.70, in premarket trading Monday. \n\n\n  The biotechnology company said before the bell that its treatment, NDV-01, demonstrated a 12-month complete response rate of 76% during a recent mid-stage study, with a favorable safety profile. \n\n\n  \"These 12-month data show the potential durability of NDV-01's clinical response profile,\" said Raj Pruthi, chief medical officer of oncology. \n\n\n  He added that the interim results provide \"meaningful clinical validation of the program\" and support the treatment's advancement into a late-stage study. \n\n\n  Relmada separately said Monday it has entered a securities purchase agreement for private investment in public equity financing, expected to result in gross proceeds of about $160 million. \n\n\n  The PIPE financing included participation several firms, including Venrock Healthcare Capital Partners, Commodore Capital and Janus Henderson Investors. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 08:30 ET (12:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}